Clinical trials: Toxic Shock Syndrome Staphylococcal
Toxic Shock Syndrome
Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study
Staphylococcus aureus and Streptococcus pyogenes produce many virulence factors. Some of them are responsible for severe infections in humans. Superantigen toxins synthesized by S. aureus or by S.
- Trial name
- IVIG (NCT02219165)
- Testing
- Intravenous human immunoglobulin, Albumin
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Staphylococcal Infection, Streptococcal Infection
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment in the acute phase of streptococcal or…
- Trial name
- IGHN2 (NCT02899702)
- Testing
- PRIVIGEN (CSL Behring), Albumin
- Where
- France
- Sponsor
- Hospices Civils de Lyon
Toxic Shock Syndrome Staphylococcal
Prodromes of Menstrual Staphylococcal Toxic Shock
Menstrual staphylococcal toxic shock is a rare but severe disease, requiring intensive care in over 80% of cases. Menstrual staphylococcal toxic shock develops during the peri-menstrual period, in healthy young women colonized by…
- Trial name
- IPro-CTSm (NCT06124599)
- Testing
- Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period, Identification of symptoms of menstrual in control patient in the last three menstrual period
- Where
- France
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Toxic Shock Syndrome Staphylococcal
Phase I STEBVax in Healthy Adults
The main purpose of this study is to test the safety of a new vaccine, STEBVax, which may lead to a useful treatment for toxic shock syndrome.
- Trial name
- NCT00974935
- Testing
- Aluminum hydroxide, STEBVax vaccine
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)